Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an
exceedingly low median overall survival of only 15 months. Current standard-of-care for …

Summary The European Association for Neuro-Oncology guideline provides
recommendations for the clinical care of adult patients with astrocytic and oligodendroglial …

Background Nearly all patients with newly diagnosed glioblastoma experience recurrence
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …

Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival
(OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with …

DNA is vulnerable to damage resulting from endogenous metabolites, environmental and
dietary carcinogens, some anti-inflammatory drugs, and genotoxic cancer therapeutics …

Cytosine methylation is a DNA modification generally associated with transcriptional
silencing. Factors that regulate methylation have been linked to human disease, yet how …

The discovery of cancer-associated alterations has primarily focused on genetic variants.
Nonetheless, altered epigenomes contribute to deregulate transcription and promote …

Glioblastoma is the most aggressive and the most common primary malignant brain tumor in
adults. Risk factors for glioblastoma are widely elusive and the clinical course is generally …

Gliomas are primary brain tumours that are thought to derive from neuroglial stem or
progenitor cells. On the basis of their histological appearance, they have been traditionally …

Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …